Nephropathy in Type 1 Diabetes Is Diminished in Carriers of HLA-DRB1*04

The Genetics of Kidneys in Diabetes (GoKinD) Study

  1. Suzanne K. Cordovado1,
  2. Yuan Zhao2,
  3. James H. Warram3,
  4. Hongguang Gong1,
  5. Karen L. Anderson2,
  6. Miyono M. Hendrix1,
  7. Laura N. Hancock1,
  8. Patricia A. Cleary2 and
  9. Patricia W. Mueller1
  1. 1Divison of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia
  2. 2Biostatics Center, George Washington University, Rockville, Maryland
  3. 3Department of Genetics and Epidemiology, Joslin Diabetes Center, Boston, Massachusetts
  1. Address correspondence and reprint requests to Suzanne Cordovado, PhD, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F-24, Atlanta, GA 30341. E-mail: snc4{at}cdc.gov

Abstract

OBJECTIVE—The purpose of this study was to examine whether known genetic risk factors for type 1 diabetes (HLA-DRB1, -DQA1, and -DQB1 and insulin locus) play a role in the etiology of diabetic nephropathy.

RESEARCH DESIGN AND METHODS—Genetic analysis of HLA-DRB1, -DQA1, -DQB1 and the insulin gene (INS) was performed in the Genetics of Kidneys in Diabetes (GoKinD) collection of DNA (European ancestry subset), which includes case patients with type 1 diabetes and nephropathy (n = 829) and control patients with type 1 diabetes but not nephropathy (n = 904). The availability of phenotypic and genotypic data on GoKinD participants allowed a detailed analysis of the association of these genes with diabetic nephropathy.

RESULTS—Diabetic probands who were homozygous for HLA-DRB1*04 were 50% less likely to have nephropathy than probands without any DRB1*04 alleles. In heterozygous carriers, a protective effect of this allele was not as clearly evident; the mode of inheritance therefore remains unclear. This association was seen in probands with both short (<28 years, P = 0.02) and long (≥28 years, P = 0.0001) duration of diabetes. A1C, a marker of sustained hyperglycemia, was increased in control probands with normoalbuminuira, despite long-duration diabetes, from 7.2 to 7.3 to 7.7% with 0, 1, and 2 copies of the DRB1*04 allele, respectively. This result is consistent with a protective effect of DRB1*04 that may allow individuals to tolerate higher levels of hyperglycemia, as measured by A1C, without developing nephropathy.

CONCLUSIONS—These data suggest that carriers of DRB1*04 are protected from some of the injurious hyperglycemic effects related to nephropathy. Interestingly, DRB1*04 appears to be both a risk allele for type 1 diabetes and a protective allele for nephropathy.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 26 November 2007. DOI: 10.2337/db07-0826.

    Additional information for this article can be found in an online appendix at http://dx.doi.org./10.2337/db07-0826.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted November 16, 2007.
    • Received June 19, 2007.
« Previous | Next Article »Table of Contents